Tadei R, Cilia G, Mathias da Silva E, Sancho Blanco G, Albacete S, Azpiazu C
Proc Biol Sci. 2025; 292(2042):20242809.
PMID: 40041960
PMC: 11881019.
DOI: 10.1098/rspb.2024.2809.
Zhang L, Guo R, Liu Y, Kong L, Zang J, Zhang Z
Sci Rep. 2025; 15(1):7383.
PMID: 40025264
PMC: 11873114.
DOI: 10.1038/s41598-025-92384-z.
Chen M, Yiu H, Wang Y, Liu T, Li C
Nanomaterials (Basel). 2025; 15(1.
PMID: 39791794
PMC: 11723374.
DOI: 10.3390/nano15010037.
Quinzo-Ortega L, Swaney W, Moore R, Rae R, Williams C
Insects. 2025; 15(12.
PMID: 39769569
PMC: 11677840.
DOI: 10.3390/insects15120967.
Berckmans Y, Ene H, Ben-Meir K, Martinez-Conde A, Wouters R, Van den Ende B
Front Oncol. 2024; 14:1402851.
PMID: 38993641
PMC: 11238040.
DOI: 10.3389/fonc.2024.1402851.
Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors.
Papp O, Jordan V, Hetey S, Balazs R, Kaszas V, Bartha A
NPJ Syst Biol Appl. 2024; 10(1):68.
PMID: 38906870
PMC: 11192759.
DOI: 10.1038/s41540-024-00394-w.
Pharmacokinetics-Pharmacodynamics Modeling for Evaluating Drug-Drug Interactions in Polypharmacy: Development and Challenges.
Zhao D, Huang P, Yu L, He Y
Clin Pharmacokinet. 2024; 63(7):919-944.
PMID: 38888813
DOI: 10.1007/s40262-024-01391-2.
Sex differences in immune protection in mice conferred by heterologous vaccines for pneumonic plague.
Davies M, Biryukov S, Rill N, Klimko C, Hunter M, Dankmeyer J
Front Immunol. 2024; 15:1397579.
PMID: 38835755
PMC: 11148226.
DOI: 10.3389/fimmu.2024.1397579.
Antiviral Activity of Seaweed against ZIKV.
de S Barros C, Cirne-Santos C, Esteves P, Gomes M, Rabelo V, Santos T
Curr Top Med Chem. 2024; 24(18):1589-1598.
PMID: 38797894
DOI: 10.2174/0115680266294503240513044930.
Single and combined exposure to 'bee safe' pesticides alter behaviour and offspring production in a ground-nesting solitary bee ().
Rondeau S, Raine N
Proc Biol Sci. 2024; 291(2019):20232939.
PMID: 38503336
PMC: 10950463.
DOI: 10.1098/rspb.2023.2939.
Resistance of HNSCC cell models to pan-FGFR inhibition depends on the EMT phenotype associating with clinical outcome.
Broghammer F, Korovina I, Gouda M, Celotti M, van Es J, Lange I
Mol Cancer. 2024; 23(1):39.
PMID: 38378518
PMC: 10880239.
DOI: 10.1186/s12943-024-01954-8.
Dual anti-HER2/EGFR inhibition synergistically increases therapeutic effects and alters tumor oxygenation in HNSCC.
Song P, Lynch S, DeMellier C, Mansur A, Gallegos C, Wright B
Sci Rep. 2024; 14(1):3771.
PMID: 38355949
PMC: 10866896.
DOI: 10.1038/s41598-024-52897-5.
Molecular Insights into the Synergistic Effects of Putrescine and Ammonium on Dinoflagellates.
Wang Y, Coyne K
Int J Mol Sci. 2024; 25(2).
PMID: 38279308
PMC: 10816187.
DOI: 10.3390/ijms25021306.
Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79b.
Seon B, Okazaki M, Duzen J, Matsuno F, Goey A, Maguire O
Leuk Res. 2024; 136():107436.
PMID: 38232613
PMC: 10906460.
DOI: 10.1016/j.leukres.2024.107436.
Antitumour effect of the mitochondrial complex III inhibitor Atovaquone in combination with anti-PD-L1 therapy in mouse cancer models.
Rodriguez-Berriguete G, Puliyadi R, Machado N, Barberis A, Prevo R, McLaughlin M
Cell Death Dis. 2024; 15(1):32.
PMID: 38212297
PMC: 10784292.
DOI: 10.1038/s41419-023-06405-8.
Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity Assay.
Stieglitz E, Gu C, Richardson M, Kita R, Santaguida M, Ali K
JCO Precis Oncol. 2023; 7:e2300302.
PMID: 37944074
PMC: 10645413.
DOI: 10.1200/PO.23.00302.
Enhancement of Radiation Therapy through Blockade of the Immune Checkpoint, V-domain Ig Suppressor of T Cell Activation (VISTA), in Melanoma and Adenocarcinoma Murine Models.
Duval K, Tavakkoli A, Kheirollah A, Soderholm H, Demidenko E, Lines J
Int J Mol Sci. 2023; 24(18).
PMID: 37762046
PMC: 10530750.
DOI: 10.3390/ijms241813742.
EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma.
Chemlal D, Varlet E, Machura A, Ovejero S, Requirand G, Robert N
Leukemia. 2023; 37(9):1925-1928.
PMID: 37532787
PMC: 10457196.
DOI: 10.1038/s41375-023-01983-0.
Screening of predicted synergistic multi-target therapies in glioblastoma identifies new treatment strategies.
Houweling M, Giczewska A, Abdul K, Nieuwenhuis N, Kucukosmanoglu A, Pastuszak K
Neurooncol Adv. 2023; 5(1):vdad073.
PMID: 37455945
PMC: 10347974.
DOI: 10.1093/noajnl/vdad073.
Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer.
Traphagen N, Schwartz G, Tau S, Roberts A, Jiang A, Hosford S
Clin Cancer Res. 2023; 29(18):3717-3728.
PMID: 37439680
PMC: 10528687.
DOI: 10.1158/1078-0432.CCR-23-0488.